ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
US Tech 100
20,832.40
0.41%
Dow Jones
42,840.26
1.18%
Brent Oil
73.035
0.44%
Bitcoin
95,823.50
0.75%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Alpha Tau Medical Ltd (DRTS) Quote

Alpha Tau Medical Ltd

Alpha Tau Medical Ltd (DRTS)

NASDAQ
3.10
-0.03
(-0.80%)
Closed December 20 4:00PM
Delayed by 15 minutes
3.10
0.00
( 0.00% )
Pre Market: 4:05AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
3.10
Bid
3.00
Ask
4.94
Volume
-
0.00 Day's Range 0.00
1.75 52 Week Range 3.40
Market Cap
215.979M
Previous Close
3.10
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
36,302
Shares Outstanding
69,670,612
Dividend Yield
-
PE Ratio
-7.41
Earnings Per Share (EPS)
-0.42
Revenue
-
Net Profit
-29.16M

About Alpha Tau Medical Ltd

Alpha Tau Medical focuses on R&D, and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer tumors. The Alpha DaRT technology was developed in 2003 at Tel Aviv University. Alpha Tau Medical focuses on R&D, and commercialization of Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) for the treatment of solid cancer tumors. The Alpha DaRT technology was developed in 2003 at Tel Aviv University.

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.alphatau.com
Headquarters
Jerusalem, Jerusalem, Isr
Founded
-
Alpha Tau Medical Ltd is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker DRTS. The last closing price for Alpha Tau Medical was $3.10. Over the last year, Alpha Tau Medical shares have traded in a share price range of $ 1.75 to $ 3.40.

Alpha Tau Medical currently has 69,670,612 shares outstanding. The market capitalization of Alpha Tau Medical is $215.98 million. Alpha Tau Medical has a price to earnings ratio (PE ratio) of -7.41.

Ask ADVFN Intelligence (AI)

DRTS Latest News

More News

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

JERUSALEM, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

December 18 2024
GlobeNewswire Inc.

Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor

JERUSALEM, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha...

December 17 2024
GlobeNewswire Inc.

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

JERUSALEM, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

December 11 2024
GlobeNewswire Inc.

Alpha Tau to Participate in Ladenburg’s Oncology Innovators & Investors Symposium

JERUSALEM, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

December 06 2024
GlobeNewswire Inc.

Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update

- Alpha DaRT® accepted into the prestigious Total Product Life Cycle Advisory Program (TAP) of the FDA, to accelerate market access to the Alpha DaRT® for patients with recurrent glioblastoma...

November 19 2024
GlobeNewswire Inc.

Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference

JERUSALEM, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

November 13 2024
GlobeNewswire Inc.

Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme

JERUSALEM, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-emitters cancer therapy Alpha...

October 21 2024
GlobeNewswire Inc.

Alpha Tau Treats First Patient with Recurrent Lung Cancer

JERUSALEM, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

October 10 2024
GlobeNewswire Inc.

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC

JERUSALEM, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha...

September 20 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

August 22 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.051.63934426233.053.23434033.13630352CS
40.7632.47863247862.343.22.34651412.93977867CS
120.7531.9148936172.353.22.11363022.64996732CS
260.8437.16814159292.263.21.75335032.431332CS
520.13.3333333333333.41.75343682.62501464CS
156-8.45-73.160173160211.5520.651.75933938.84214544CS
260-8.45-73.160173160211.5520.651.75933938.84214544CS

DRTS - Frequently Asked Questions (FAQ)

What is the current Alpha Tau Medical share price?
The current share price of Alpha Tau Medical is $ 3.10
How many Alpha Tau Medical shares are in issue?
Alpha Tau Medical has 69,670,612 shares in issue
What is the market cap of Alpha Tau Medical?
The market capitalisation of Alpha Tau Medical is USD 215.98M
What is the 1 year trading range for Alpha Tau Medical share price?
Alpha Tau Medical has traded in the range of $ 1.75 to $ 3.40 during the past year
What is the PE ratio of Alpha Tau Medical?
The price to earnings ratio of Alpha Tau Medical is -7.41
What is the reporting currency for Alpha Tau Medical?
Alpha Tau Medical reports financial results in USD
What is the latest annual profit for Alpha Tau Medical?
The latest annual profit of Alpha Tau Medical is USD -29.16M
What is the registered address of Alpha Tau Medical?
The registered address for Alpha Tau Medical is KIRYAT HAMADA ST. 5, JERUSALEM, JERUSALEM, 9777605
What is the Alpha Tau Medical website address?
The website address for Alpha Tau Medical is www.alphatau.com
Which industry sector does Alpha Tau Medical operate in?
Alpha Tau Medical operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PHIOPhio Pharmaceuticals Corporation
$ 4.30
(144.32%)
247.18k
EDBLEdible Garden AG Inc
$ 0.4568
(92.18%)
4.27M
BNRGBrenmiller Energy Ltd
$ 1.13
(50.01%)
659.23k
RUMRumble Inc
$ 10.11
(40.61%)
182.61k
PTIXProtagenic Therapeutics Inc
$ 0.79
(31.64%)
7.03k
ABPAbpro Holdings Inc
$ 1.61
(-22.22%)
5.29k
CNTMConnectM Technology Solutions Inc
$ 0.82
(-21.15%)
2.1k
HSDTHelius Medical Technologies Inc
$ 0.7257
(-20.25%)
15.81k
TPICTPI Composites Inc
$ 1.95
(-18.75%)
34.38k
NVNINVNI Group Ltd
$ 7.18
(-16.32%)
24.86k
EDBLEdible Garden AG Inc
$ 0.4474
(88.22%)
4.28M
LAESSEALSQ Corporation
$ 3.20
(16.36%)
1.72M
RGTIRigetti Computing Inc
$ 10.32
(10.14%)
721.53k
BNRGBrenmiller Energy Ltd
$ 1.14
(51.33%)
673.84k
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 32.12
(5.38%)
476.41k

DRTS Discussion

View Posts
PonkenPlonken PonkenPlonken 16 hours ago
https://www.ourcrowd.com/startup-news/alpha-tau-100-complete-response-rate-in-skin-cancer-trial?
might become SOC in inoperable tumors - super tech - revolutionize radio
👍️0
PonkenPlonken PonkenPlonken 16 hours ago
has a lot of critical readouts coming soon - see below
neglected and forgotten...
👍️0
PonkenPlonken PonkenPlonken 5 days ago
https://www.alphatau.com/single-post/alpha-tau-healthcare-capital-corp-to-combine-and-create-a-1-billion-publicly-traded-company
👍️0
PonkenPlonken PonkenPlonken 3 weeks ago
Great Israeli company -- coming to life ahead of a few readouts
👍️0
theswordman theswordman 1 month ago
3rd QTR update: 2+ years op cash. Trial expansion.
FDA accepted for TAP--Total Product Life Cycle Advisory Program (TAP)
FDA approval of an Investigational Device Exemption (IDE) application for cSCC

https://www.alphatau.com/single-post/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 2 months ago
AlphaTau into the FDAs TPLC program: https://www.alphatau.com/single-post/alpha-tau-announces-acceptance-into-fda-s-total-product-life-cycle-advisory-program-to-accelerate-ma

Here is link that explains what that program helps with : https://www.fda.gov/medical-devices/how-study-and-market-your-device/total-product-life-cycle-advisory-program-tap
👍️0
theswordman theswordman 2 months ago
1st lung cancer patient treated--https://www.alphatau.com/single-post/alpha-tau-treats-first-patient-with-recurrent-lung-cancer

“The treatment makes use of bronchoscopic endobronchial ultrasound to insert the Alpha DaRT sources.

examining its application to an organ such the lung, given its proximity to vital healthy organs, may hopefully open new doors to a global population of patients with otherwise poor treatment options
👍️0
theswordman theswordman 3 months ago
Emory Univ wants another trial for subpopulation

https://www.alphatau.com/single-post/fda-approval-of-ide-to-initiate-multi-center-investigator-initiated-study-of-alpha-dart-in-immunoco
👍️0
theswordman theswordman 3 months ago
The big boys are correct. Just a little off ontheir delivery and MOA

https://www.cnbc.com/2024/09/16/radiopharmaceuticals-race-heats-up-as-drugmakers-chase-novartis.html
👍️0
theswordman theswordman 4 months ago
2nd qtr update

https://www.alphatau.com/single-post/alpha-tau-medical-announces-second-quarter-2024-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 6 months ago
Atlanta TV discussing AlphaDart trial at Emory Univ.

https://www.atlantanewsfirst.com/2024/06/25/emory-doctor-hopeful-about-clinical-trial-new-skin-cancer-treatment/

https://clinicaltrials.gov/study/NCT05323253?term=alpha%20tau&intr=alpha%20dart&page=2&rank=20#study-overview
👍️0
theswordman theswordman 6 months ago
Publication in Cancers Journal of Long-Term Safety and Efficacy Data in Multiple Hard-to-Treat Superficial Cancers

https://www.alphatau.com/single-post/alpha-tau-announces-publication-in-cancers-journal-of-long-term-safety-and-efficacy-data-in-multiple
👍️0
Monksdream Monksdream 6 months ago
DRTS under $3
👍️0
theswordman theswordman 7 months ago
https://www.alphatau.com/single-post/alpha-tau-medical-announces-first-quarter-2024-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 7 months ago
https://www.alphatau.com/single-post/alpha-tau-announces-alpha-dart-treatment-of-first-patient-with-liver-metastases-of-colorectal-cancer
👍️0
theswordman theswordman 8 months ago
Bassett is one of two Alpha DaRT trial sites in New York State, the other being Memorial Sloan Kettering Cancer Center in New York City.

https://www.allotsego.com/skin-cancer-treatment-trials-open/
👍️0
theswordman theswordman 8 months ago
March Investor Deck

https://www.alphatau.com/_files/ugd/89ab89_701f2ad74a4c4684b223cb427cf79506.pdf
👍️0
theswordman theswordman 1 year ago
AlphaTau--Sidoti Conference

https://www.alphatau.com/single-post/alpha-tau-to-participate-in-sidoti-small-cap-conference

OR

https://www.meetmax.com/sched/event_98459/conference_presentations.html?bank_access=0&event_id=98459

This is from 07 DEC (THURS) @ 9:15 AM
👍️0
theswordman theswordman 1 year ago
Pancreatic Cancer Trial--early results
https://www.alphatau.com/single-post/highly-promising-interim-results-of-alpha-dart-treatment-of-advanced-pancreatic-cancer
👍️0
theswordman theswordman 1 year ago
Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) has accepted Alpha Tau’s submission requesting shonin pre-market approval of Alpha DaRT in patients with recurrent head & neck cancer

https://www.alphatau.com/single-post/atm-submits-to-japanese-pmda-for-pre-market-approval-of-alpha-dart-for-recurrent-head-neck-cancer
👍️0
theswordman theswordman 1 year ago
CORP UPDATE

https://finance.yahoo.com/news/alpha-tau-medical-announces-third-213000260.html?.tsrc=rss
👍️0
theswordman theswordman 1 year ago
New video presentation. Updates about Hahn@SAB. New manuf facility.

👍️0
theswordman theswordman 1 year ago
Alpha Tau adds another manuf facility in U.S. So this is certainly getting ahead (cart before the horse??)
https://www.alphatau.com/single-post/atm-enters-into-long-term-lease-of-site-in-new-hampshire-for-second-u-s-manufacturing-facility

The Hudson site promises to be larger than our existing Lawrence site, and is expected to support our goals of materially scaling up capacity as well as achieving manufacturing redundancy
👍️0
theswordman theswordman 1 year ago
Hahn joins Science Advisor Board

https://www.marketscreener.com/quote/stock/ALPHA-TAU-MEDICAL-LTD-134583875/news/Alpha-Tau-Medical-Ltd-Announces-Stephen-M-Hahn-Joins-Scientific-Advisory-Board-45136482/
👍️0
theswordman theswordman 1 year ago
Latest DRTS presentation
👍️0
theswordman theswordman 1 year ago
2nd patient treated for inoperable pancreatic cancer. 1St was in Montreal

https://www.globenewswire.com/news-release/2023/09/14/2743253/0/en/Alpha-Tau-Treats-First-Patient-with-Advanced-Inoperable-Pancreatic-Cancer-at-Israel-s-Hadassah-Medical-Center.html
👍️0
Awl416 Awl416 1 year ago
Alpha Tau Announces Robust Long-Term Safety and Efficacy Data from Multiple Clinical Trials of Alpha DaRT
👍️0
theswordman theswordman 2 years ago
New K O L event

👍️0
theswordman theswordman 2 years ago
CORP UPDATE

https://www.alphatau.com/single-post/alpha-tau-medical-announces-first-quarter-2023-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 2 years ago
With our Breakthrough Device Designation for the treatment of certain patients with squamous cell carcinoma, we look forward to swift accrual into our U.S. pivotal ReSTART trial, with the goal of bringing the Alpha DaRT closer to availability for patients as quickly as possible."

The results of the trial demonstrated that the treatment was successfully delivered to ten of ten patients, with a 100% CR observed at 12 and 24 weeks,

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804784
👍️0
theswordman theswordman 2 years ago
New buy rating

https://beststocks.com/alpha-tau-medical-receives-buy-rating-and-hig/
👍️0
theswordman theswordman 2 years ago
Alpha Tau enrolled the 1st patrient in their 30 patient pancreatic cancer trial

https://www.clinicaltrials.gov/ct2/show/NCT04002479.

Read about the milestone here

https://www.alphatau.com/single-post/alpha-tau-jgh-announce-alpha-dart-treatment-of-first-patient-in-pancreatic-cancer-clinical-trial
👍️0
theswordman theswordman 2 years ago
New video

👍️0
theswordman theswordman 2 years ago
Treatment of 1st two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial

https://www.alphatau.com/single-post/treatment-of-1st-two-patients-in-its-pivotal-multicenter-recurrent-skin-cancer-restart-trial
👍️0
theswordman theswordman 2 years ago
Cash & equivalents balance of $105.4 million, with runway for at least two years

https://www.alphatau.com/single-post/alpha-tau-medical-announces-full-year-2022-financial-results-and-provides-corporate-update
👍️0
theswordman theswordman 2 years ago
https://www.alphatau.com/single-post/health-canada-authorization-for-alpha-dart-clinical-trial-for-the-treatment-of-liver-metastases
👍️ 1
theswordman theswordman 2 years ago
100% response rate!!!!!!!!!!!!!!!!!!!!!!!!!

👍️0
theswordman theswordman 2 years ago
Several good pieces of news

https://newsfilter.io/a/265287a70404d81a19c29eab7e95abca
👍️0
theswordman theswordman 2 years ago
Alpha Tau Medical Ltd. (the “Company”) hereby furnishes the following documents:

(i) notice and proxy statement with respect to the Company’s annual general meeting of shareholders (the “Meeting”) to be held at 4:30 p.m. (Israel time), on November 2, 2022, at the Company’s headquarters at 5 Kiryat Hamada St., Jerusalem 9777605, Israel, describing proposals to be voted upon at the Meeting, the procedure for voting in person or by proxy at the Meeting and various other details related to the Meeting; and
(ii) a proxy card for use in connection with the Meeting.

The proxy statement is furnished with this report of foreign private issuer on Form 6-K (this “Form 6-K”) as Exhibit 99.1 and the proxy cards are furnished with this Form 6-K Exhibits 99.2 and 99.3.

This Form 6-K is incorporated by reference into the Company’s registration statement on Form S-8 (File No. 333-264169).
👍️0
theswordman theswordman 2 years ago
GOOD READ!!!

https://medium.com/wadepthealth/washington-is-one-of-first-states-to-license-promising-new-cancer-treatment-59c42162e25b
👍️0
theswordman theswordman 2 years ago
18 JUL--11 AM EASTERN--free to register


https://finance.yahoo.com/news/alpha-tau-hosting-key-opinion-200100611.html
👍️0
theswordman theswordman 2 years ago
Patient, 60, is given alpha-radiation to target the tumor without harming healthy tissue in ‘historical’ procedure

https://nocamels.com/2022/06/israeli-researchers-use-breakthrough-tech-to-treat-prostate-cancer-for-first-time/
👍️0
theswordman theswordman 3 years ago
1st Prostate Cancer patient treated!!!!

https://www.prnewswire.com/news-releases/alpha-tau-announces-treatment-of-first-prostate-cancer-patient-with-alpha-dart-301573470.html
👍️0
theswordman theswordman 3 years ago
On June 16, 2022, Alpha Tau Medical Ltd. (the “Company”) issued a press release titled “Alpha Tau Announces Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site, Amended Radioactive License with Increased Capacity at Lawrence, MA Site.” A copy of this press release is attached to this Form 6-K as Exhibit 99.1.


https://newsfilter.io/a/90df70ad4fbbeb233fae5d6cea6e9dce
👍️0
theswordman theswordman 3 years ago
https://www.prnewswire.com/news-releases/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-pivotal-study-of-alpha-dart-in-recurrent-cutaneous-scc-301564017.html
👍️0
theswordman theswordman 3 years ago
NEW MAY 2022 INVESTOR PRESENTATION

Link goes to webpage for PDF download

https://www.alphatau.com/events
👍️0
theswordman theswordman 3 years ago
DRTS: Alpha Tau: First Alpha DaRT Patients Treated in France as Part of Alpha DaRT Multicenter Skin Cancer Trial

https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20220523090518DRTS&utm_campaign=inplay&utm_medium=social&utm_source=twitter&utm_content=view_page
👍️0
theswordman theswordman 3 years ago
Form F-1 filed

https://newsfilter.io/a/a2246fdd4e4ed658cd4c86741101f8c0
👍️0
theswordman theswordman 3 years ago
CantorFitz initiates coverage of AlphaTau

https://biotuesdays.com/2022/04/14/cantor-starts-alpha-tau-medical-at-ow-pt-20/
👍️0
theswordman theswordman 3 years ago
https://seekingalpha.com/article/4500989-alpha-tau-treating-cancer-with-precision-alpha-radiation?utm_source=stck.pro&utm_medium=referral
👍️0

Your Recent History

NASDAQ
DRTS
Alpha Tau Medical
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads